Huston Jessica, Orey Dontia, Kumar Ashish, Ashchi Andrew, Ashchi Andrea, Berner Jason, Alkhouri Yazan, Sutton David, Deeb Wasim, Bisharat Mohannad, Goldfaden Rebecca F
Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, 580 W. 8th Street, Jacksonville, FL, USA.
East Coast Institute for Research, 3550 University Blvd S #101, Jacksonville, FL, USA.
Am J Cardiovasc Drugs. 2025 May;25(3):329-336. doi: 10.1007/s40256-024-00713-w. Epub 2024 Dec 31.
Patients with hypertension are at an increased risk of cardiovascular disease and death. Resistant hypertension, or hypertension that is unsuccessfully treated with multiple antihypertensive medications, further exacerbates the complications and negative outcomes for patients. A new pathway, via aldosterone synthesis inhibition, is currently being studied as a method to reduce blood pressure values in patients who are currently taking other antihypertensive medications. This review presents and discusses the current pharmacokinetic, pharmacodynamic, and clinical and scientific evidence pertaining to baxdrostat, a novel aldosterone synthase inhibitor.
高血压患者患心血管疾病和死亡的风险增加。顽固性高血压，即使用多种抗高血压药物治疗未成功的高血压，会进一步加重患者的并发症和不良后果。目前正在研究一种通过抑制醛固酮合成来降低正在服用其他抗高血压药物患者血压值的新途径。本综述介绍并讨论了与新型醛固酮合酶抑制剂巴多司他相关的当前药代动力学、药效学以及临床和科学证据。
